Startups

Our startups

Be inspired. Search our startups.

Filter
Startups
2017  Finalist
Therapeutics (Pharma / Biotech)

We want to keep people out of the hospital by preventing disease using vaccines and immunity enhancing therapeutics. Our patented delivery system is differentiated because it’s non-toxic, economical to make and easy to purify. We are seeking funding to complete a clinical trial for our lead influenza vaccine candidate and to test our technology in other diseases. There are many opportunities to apply our platform technology in infectious diseases, allergy and cancer.

2017  Finalist
Therapeutics (Pharma / Biotech)

T cell therapy is a rapidly growing form of cancer treatment and many pharmaceutical companies are developing these therapies, all of which are still in the clinical trial stage. Despite positive results, a major problem called cross-reactivity is affecting the industry. In some cases, patients have died as a result of this cross-reactive side effect. As a service provider to pharmaceutical companies Structured Immunity has the patent pending technology to solve the problem of cross-reactivity.

2017  Finalist
Therapeutics (Pharma / Biotech)

Drug-resistant infections have become a public health crisis. We are at the precipice of the post-antibiotic era, where routine surgeries and standard in-patient care present unacceptable risk. Octagon has developed a novel approach to antibiotic discovery, which utilizes bacterial metabolism as a therapeutic target. Our lead development candidates, which show no effect in standard industry screens, have been shown safe and highly effective in animal models. This is a critical medical need.

2017  Finalist
Medical Devices

Cellino’s goal is to enable gene therapy companies and research labs to deliver gene-editing cargo to cells with exceptional performance, which is a major challenge today.

2017  Finalist
Therapeutics (Pharma / Biotech)

47% of all dogs over the age of 10 will die from cancer. With current treatment options expensive and potentially leading to negative side effects, Torigen is focused on commercializing, VetiVax, a novel, personalized immunotherapy that uses the animals’ own tumor cells to fight the cancer.

Using a surgically excised portion of tumor tissue, we create a series of treatments that are given back to the animal to help stimulate their immune system to fight cancer, safely and inexpensively.

2017  Finalist
Therapeutics (Pharma / Biotech)

ReviveMed is a precision-medicine platform that leverages the data from small molecules or metabolites. ReviveMed technology, which was developed at MIT and published in Nature Methods, uniquely overcomes the difficulty of using a large set of metabolomic data, and transform these data into actionable insight. Currently, we selected a few strategic clients from leading pharma/biotech companies to provide them with drug de-risking, biomarker discovery and therapeutic solutions.

2017  Finalist
Medical Devices

NerveSolutions develops devices to repair large gaps in nerves injured by trauma or surgery. In cases like amputation nerves cannot be repaired. Their drive to reconnect to their former targets instead creates a tangled and swollen neuroma - a source of debilitating pain for 20-30% of amputees. No standard of care exists for long-gap repair or neuroma prevention/treatment. Our lead device is NervLok, a patent-pending bioengineered device that is placed onto the cut nerve-end to prevent neuroma.

2017  Finalist
Therapeutics (Pharma / Biotech)

The widespread irreproducibility in biomedical science is making scientific ‘experts’ obsolete. Hive leverages an innovative model to extract information from the scientific literature on a large-scale while providing confidence metrics that directly assess reproducibility of scientific findings. Hive offers business development executives, venture capitalists, and researchers the extraordinary ability to develop their expertise on any topic in biomedicine within a short period of time.

2017  Finalist
Therapeutics (Pharma / Biotech)

We de-risk biotech investment with a diverse pipeline sourced from tech transfer portfolios at top-tier research institutes.

Our flagship program — Nivien Therapeutics — is an oncology platform derived from Harvard Medical School. Our secondary programs range from opioid harm reduction to thermotolerant enzymes for industrial clean-in-place.

When you invest in General Biotechnologies, you don't just buy equity in one company — You buy equity in the future of biotechnology.

2017  Finalist
Therapeutics (Pharma / Biotech)

Akanocure is developing a group of novel bio-inspired anti-cancer next generation small molecules (SGSM) that would have the affinities and elicit the protein-protein interaction modulation of macromolecules while retaining the high tumor permeability of small molecules. SGSM are designed to be inexpensive to develop, avoid the side effects of chemotherapy, elicit response in most patients, suppress metastasis and relapse, and could be synergistic when combined with immunotherapies.